Hypermethylation of the glutathione S-transferase mu 2 (GSTM2) promoter has been identified as a potential biomarker for aggressive tumor behavior and may contribute to the progression of estrogen receptor (ER)-and progesterone receptor (PR)-negative BRCA (9). Here, GSTM2 is linked to neoplasm.